



The Galien Foundation Announces Nominations are Now Open for the 2022 Prix Galien UK Awards

Regarded as the Equivalent of the Nobel Prize for the Life Sciences Industry, Awards to Recognise “Best Biotechnology Product,” “Best Digital Health Solution,” “Best Medical Technology” and “Best Pharmaceutical Product”

LONDON, 17 February 2022 — The Galien Foundation, the premier global institution dedicated to honouring innovators in life sciences, today announced nominations for the 2022 Prix Galien UK Awards are now open. The four award categories, “Best Pharmaceutical Product,” “Best Biotechnology Product,” “Best Medical Technology” and “Best Digital Health Solution” recognise excellence in biopharmaceutical and medical technology innovations that improve the human condition. Winners will be announced on 12 May at the Natural History Museum in London.

To qualify for the 2022 Prix Galien UK Awards, please find the criteria for each product category below. The award committee will review what was innovative during the product’s scientific development, application, or clinical utility, what was learned for the future of biomedical science from the product’s introduction to the clinic and what impact the product has had on human health. For additional nomination criteria and to submit your product for an award, please visit <http://candidates.prixgalien.uk/submissions/home>. Submissions close on 23 March 2022.

“Best Pharmaceutical Product” and “Best Biotechnology Product”

The Prix Galien UK Award for “Best Pharmaceutical Product” is open to any medicine that has been developed to prevent, cure and/or treat disease that has had a significant, positive impact on improving patient lives. The Prix Galien UK Award for “Best Biotechnology Product” is open to any biologic medicine (i.e., vaccines, ATMPs, recombinant proteins, monoclonal antibodies) that has had a significant, positive impact on improving patient lives can submit for this category.

Eligibility criteria:

- Products must have received marketing approval between 31 December 2016 – 31 December 2021. Products that have received approval prior to 31 December 2016 are eligible for submission only if a new indication has been granted within the last five years.
- We accept nominations for individual products, not classes of products. We assume that nominees possess permission of the current owner(s) of the product rights.

“Best Medical Technology”

The Prix Galien UK Award for “Best Medical Technology” is open to any instrument, apparatus, appliance, software, material or other article (whether used alone or in combination together with any accessories, including software used specifically for diagnostic and/or therapeutic purposes) that has had a significant, positive impact on improving patient lives.

Eligibility criteria:

- Products granted a CE mark between 31 December 2016 – 31 December 2021.
- We accept nominations for individual products, not classes of products. We assume that nominees possess permission of the current owner(s) of the product rights.



“Best Digital Health Solution”

The Prix Galien UK Award for the “Best Digital Health Solution” is open to any evidenced-based digital product that has demonstrated a significant, positive impact on improving patient lives.

Eligibility criteria*:

- Products must be clinically validated (minimum 2 peer reviewed papers) or have been approved by the MHRA
- Evidence of sustained growth and patient satisfaction over the past three years
- Revenue Based > £350K in the past 12 months
- At least 10 or more employees at the start of the period
- We accept nominations for individual products, not classes of products. We assume that nominees possess permission of the current owner(s) of the product rights
- *3 criteria must be met to be eligible

“I’m delighted and honoured to be a part of the celebration recognising the greatest innovators in health,” said Professor Sir Mark Walport, Honorary Distinguished Professor of Medicine, Imperial College, and Prix Galien UK Committee Chair. “By recognising their landmark achievements with Prix Galien UK Awards, we can look back at how far we’ve come, while inspiring us all to work harder on our commitment to improving the future of patient care.”

The Galien Foundation has a longstanding tradition of bringing the best in the pharmaceutical, biotechnology, medical device and digital health industries together to commemorate success in research, development and innovation, celebrating 50 years of excellence in scientific innovations at the 2022 Prix Galien USA Awards in New York City. Worldwide, the Prix Galien is regarded as the equivalent of the Nobel Prize for the life sciences industry.

The Prix Galien UK Awards launched in 1990 and have been awarded to 36 products since inception. Winners are selected every two years by the Prix Galien UK Awards Committee, which is comprised of 14 members who are experts in the field and share a passion for improving health and driving innovation. Top innovators, such as Anylam, Novartis, and Novo Nordisk A/S, will be among the 2022 Prix Galien UK nominees.

“Researchers in the United Kingdom are consistently at the forefront of health innovation, moving the needle forward to help save and improve lives,” said Bruno Cohen, Chairman of The Galien Foundation. “We’re excited to once again celebrate those invaluable contributions at The Prix Galien UK Awards this year.”

For questions regarding submissions for a 2022 Prix Galien UK award, please reach out to Robin Welbers, robin@galienfoundation.org, (917) 781-0521, or Laetitia Parienti, lparienti@galienfoundation.org.

Prix Galien UK Awards Committee 2022

Professor Sir Mark WALPORT



Honorary Distinguished Professor of Medicine, Imperial College
Committee Chair

Dr Jane ADAM
Chair, NICE Technology Appraisal Committee and Consultant, St George's University Hospitals NHS
Foundation Trust

Professor Bruce CAMPBELL
Consultant Vascular Surgeon, Exeter

Ms Tabitha GOLDSTAUB, MBE
Co-founder of CognitionX

Dame Parveen KUMAR, DBE
Emeritus Professor of Medicine and Education, Queen Mary University of London

Sir Robert LECHLER
Emeritus Senior Vice President (health), King's College London

Sir Munir PIRMOHAMED
David Weatherall Chair of Medicine, University of Liverpool, Liverpool

Dame June RAINE
Chief Executive, Medicines and Healthcare products Regulatory Agency

Professor Duncan RICHARDS
Professor of Clinical Therapeutics, University of Oxford

Professor Liam SMEETH
Professor of Clinical Epidemiology and Director of the London School of Hygiene and Tropical Medicine

Professor Rosalind SMYTH, CBE
Director and Professor of Child Health, UCL, Great Ormond St. Institute of Child Health

Professor David WEBB, CBE
Christison Chair of Therapeutics & Clinical Pharmacology, University of Edinburgh

Professor Moira WHYTE, OBE
Vice Principal and Head of the College of Medicine and Veterinary Medicine, Sir John Crofton Professor
of Respiratory Medicine, University of Edinburgh

Professor Elizabeth WILLIAMSON
Professor of Biostatistics and Health Data Science, London School of Hygiene & Tropical Medicine

About the Galien Foundation



The Galien Foundation fosters, recognises and rewards excellence in scientific innovation to improve the state of human health. Our vision is to be the catalyst for the development of the next generation of innovative treatments and technologies that will impact the state of medical practice and save lives.

The Foundation oversees and directs activities in the UK for the Prix Galien, an international awards program dedicated to progress through innovative medicines development, with chapters in 14 countries and Africa. The Prix Galien was created in 1970 by Roland Mehl in honour of Galien, the father of medical science and modern pharmacology. Worldwide, the Prix Galien is regarded as the equivalent of the Nobel Prize in biopharmaceutical research.

For more information, visit www.galienfoundation.org.

Follow the Foundation on social media:

<https://www.facebook.com/GalienFoundation/>

<https://twitter.com/GalienFdn>

<https://www.linkedin.com/company/the-galien-foundation/>

Media Contact (UK):

Julian Tyndale-Biscoe

Finn Partners

Julian.Tyndale-biscoe@finnpartners.com

+44 20 3217 7060

Media Contact (Global):

Kara Bradley

Finn Partners

Kara.Bradley@finnpartners.com

646-213-7243

###